EE200000321A - Uudsed ühendid - Google Patents

Uudsed ühendid

Info

Publication number
EE200000321A
EE200000321A EEP200000321A EEP200000321A EE200000321A EE 200000321 A EE200000321 A EE 200000321A EE P200000321 A EEP200000321 A EE P200000321A EE P200000321 A EEP200000321 A EE P200000321A EE 200000321 A EE200000321 A EE 200000321A
Authority
EE
Estonia
Prior art keywords
novel compounds
novel
compounds
Prior art date
Application number
EEP200000321A
Other languages
English (en)
Inventor
Baxter Andrew
Cheshire David
Mcinally Thomas
Mortimore Michael
Cladingboel David
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of EE200000321A publication Critical patent/EE200000321A/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200000321A 1997-12-05 1998-12-01 Uudsed ühendid EE200000321A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704546A SE9704546D0 (sv) 1997-12-05 1997-12-05 Novel compounds
PCT/SE1998/002190 WO1999029686A1 (en) 1997-12-05 1998-12-01 Novel compounds

Publications (1)

Publication Number Publication Date
EE200000321A true EE200000321A (et) 2001-08-15

Family

ID=20409283

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000321A EE200000321A (et) 1997-12-05 1998-12-01 Uudsed ühendid

Country Status (16)

Country Link
EP (1) EP1037889A1 (et)
JP (1) JP2001525406A (et)
KR (1) KR20010032800A (et)
CN (1) CN1284074A (et)
AU (1) AU1791599A (et)
BR (1) BR9813378A (et)
CA (1) CA2312357A1 (et)
EE (1) EE200000321A (et)
HU (1) HUP0100731A3 (et)
IL (1) IL136368A0 (et)
NO (1) NO20002787L (et)
PL (1) PL340837A1 (et)
SE (1) SE9704546D0 (et)
SK (1) SK8442000A3 (et)
TR (1) TR200001544T2 (et)
WO (1) WO1999029686A1 (et)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901875D0 (sv) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
JP2002330787A (ja) * 2000-10-21 2002-11-19 Astrazeneca Ab 化学物質
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
ATE355273T1 (de) 2003-05-12 2006-03-15 Pfizer Prod Inc Benzamidinhibitoren des p2x7-rezeptors
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
WO2006003500A1 (en) 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
CA2645551C (en) 2006-03-16 2016-06-28 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
DK2001474T3 (en) 2006-03-16 2016-05-09 Second Genome Inc BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為p2x7調節劑之雙環雜芳基化合物與其用途
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
MX2009000117A (es) * 2006-07-06 2009-01-23 Glaxo Group Ltd N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso.
GB0613473D0 (en) * 2006-07-06 2006-08-16 Glaxo Group Ltd Novel compounds
JP2010520875A (ja) 2007-03-09 2010-06-17 レノビス, インコーポレイテッド P2x7調節因子としてのビシクロヘテロアリール化合物およびその使用
EP2139858A1 (en) * 2007-03-28 2010-01-06 Glaxo Group Limited Piperidinone carboxamide derivatives as p2x7 modulators
WO2008119685A2 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
MX2009010759A (es) * 2007-04-03 2009-10-28 Glaxo Group Ltd Derivados de carboxamida imidazolidina como modulares de p2x7.
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system
BRPI0910034B1 (pt) 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag Antagonistas do p2x7r e composições farmacêuticas que os compreendem
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
SG185400A1 (en) 2010-05-14 2012-12-28 Affectis Pharmaceuticals Ag Novel methods for the preparation of p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2019102354A1 (en) 2017-11-21 2019-05-31 3M Innovative Properties Company Oral plant-based-oil-in-water emulsions and methods of use
CN111511362A (zh) 2017-12-20 2020-08-07 3M创新有限公司 口腔组合物及使用方法
CN111511348A (zh) 2017-12-20 2020-08-07 3M创新有限公司 口腔组合物及使用方法
CN113271909A (zh) 2018-12-29 2021-08-17 3M创新有限公司 口腔制品及使用方法
WO2020136620A1 (en) 2018-12-29 2020-07-02 3M Innovative Properties Company Oral articles and methods of use

Also Published As

Publication number Publication date
HUP0100731A2 (hu) 2002-05-29
TR200001544T2 (tr) 2000-11-21
KR20010032800A (ko) 2001-04-25
AU1791599A (en) 1999-06-28
NO20002787D0 (no) 2000-05-31
JP2001525406A (ja) 2001-12-11
PL340837A1 (en) 2001-02-26
IL136368A0 (en) 2001-06-14
HUP0100731A3 (en) 2002-08-28
SK8442000A3 (en) 2001-01-18
CA2312357A1 (en) 1999-06-17
EP1037889A1 (en) 2000-09-27
CN1284074A (zh) 2001-02-14
BR9813378A (pt) 2000-10-10
WO1999029686A1 (en) 1999-06-17
NO20002787L (no) 2000-08-01
SE9704546D0 (sv) 1997-12-05

Similar Documents

Publication Publication Date Title
PT860428E (pt) Compostos pirimidiona
IS5479A (is) Efnasambönd
EE200000321A (et) Uudsed ühendid
IS5478A (is) Efnasambönd
IS5477A (is) Efnasambönd
ID22850A (id) Senyawa-senyawa pirazina
EE200000044A (et) Uued ühendid
NO994877D0 (no) Kalsilytiske forbindelser
ID20323A (id) Senyawa-senyawa triazinilaminostilbena
IS5208A (is) Efnasambönd
EE9900475A (et) Ühendid
IS5323A (is) Efnasambönd
ID22983A (id) Senyawa-senyawa fluorometoksimino
EE9900466A (et) Ühendid
DE69737634D1 (de) Insektizide oxadiazinverbindungen
SE9702775D0 (sv) Novel compounds
SE9703735D0 (sv) Novel compounds
SE9701194D0 (sv) Novel compounds
SE9702199D0 (sv) Novel compounds
SE9702652D0 (sv) Novel compounds
SE9704403D0 (sv) Novel compounds
SE9702198D0 (sv) Novel compounds
SE9702197D0 (sv) Novel compounds
SE9704402D0 (sv) Novel compounds
SE9701766D0 (sv) Novel compounds